TMCnet News

LifeCell Obtains Preliminary Injunction Preventing TELA Bio's Launch of Its TELAMax Hernia Mesh
[May 19, 2015]

LifeCell Obtains Preliminary Injunction Preventing TELA Bio's Launch of Its TELAMax Hernia Mesh


Acelity today announced that the Superior Court of New Jersey, Somerset County, has granted LifeCell Corporation's request for a preliminary injunction in a trade secret and unfair competition case against TELA Bio, Inc. and two of its executive officers.

The preliminary injunction (Case No. SOM-C-12013-15) prohibits TELA Bio from selling TELAMax, its hernia mesh product, in the United States until the completion of a trial, which has not yet been scheduled. In addition, the injunction prevents TELA Bio from recruiting or hiring current or former LifeCell employees and restrains TELA Bio from destroying evidence in this case.

"Acelity and LifeCell will vigorously protect our company and proprietary technology from unfair business practices," said John Bibb, Executive Vice President and General Counsel. "Our heritage of continuous innovation is what enables LifeCell to deliver industry-leading products that transform the lives of patients around the world. This case demonstrates our unwavering commitment to protecting our intellectual property and our most valuable resources - our people and products."



The injunction was granted based on a complaint filed by LifeCell in March alleging, among other things, that TELA Bio and two of its founders misappropriated trade secrets and proprietary information and engaged in unfair competition. The Court initially granted a temporary restraining order against TELA Bio in March, and following a hearing on April 30, the Court granted LifeCell's request for a preliminary injunction on May 8.

About LifeCell


LifeCell, an Acelity Company, develops and markets innovative products for reconstructive, cosmetic and general surgery. Core LifeCell™ products include: AlloDerm® Regenerative Tissue Matrix and Strattice™ Reconstructive Tissue Matrix for breast reconstruction, revision and abdominal wall repair surgery; and REVOLVE™ System for high-volume fat processing.

About Acelity

Acelity is a global wound care and regenerative medicine company created by uniting the strengths of three companies, Kinetic Concepts, Inc., LifeCell Corporation and Systagenix Wound Management, Limited. We are committed to advancing the science of healing and restoring people's lives. Available in more than 75 countries, the innovative and complementary Acelity product portfolio delivers value through solutions that speed healing and lead the industry in quality, safety and customer experience. Headquartered in San Antonio, Texas, Acelity employs more than 5,500 people around the world. We believe in enabling better futures for everyone. Please visit acelity.com.


[ Back To TMCnet.com's Homepage ]